Acquisition, In-Licensing Arrangement, Sale of Investment, Research and Development Arrangement and Collaborative Arrangement - Collaborative Arrangement (Detail) - Collaborative Arrangement [Member] - Innovent [Member] $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended |
|---|---|---|---|
|
May 31, 2026
USD ($)
program
medicine
|
Sep. 27, 2026
USD ($)
|
Sep. 27, 2026
USD ($)
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Number of early-stage and de novo cancer medicines | medicine | 12 | ||
| Upfront payment to collaborators | $ 650 | $ 650 | $ 650 |
| Number of co-developed and co-commercialized programs | program | 4 | ||
| Maximum | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Eligible development, regulatory and sales-based milestone payments | $ 9,850 |